Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia

Francesco Frassoni, Myriam Labopin, Ray Powles, Jean Yves Mary, William Arcese, Andrea Bacigalupo, Donald Bunjes, Eliane Gluckman, Tapani Ruutu, Ulrich W. Schaefer, Jorge Sierra, Jean Paul Vernant, Roel Willemze, Theo De Witte, Norbert Claude Gorin

Research output: Contribution to journalArticle

Abstract

Background: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors known previously to influence outcome and a stratified analysis that initially defined, by multivariate analysis, significant variables in this study and then used a proportional-hazard model including centres. Findings: The overall results at 3 years were 57% (95% C1 53-61) for leukaemia-free survival (LFS), 23% (19-27) for relapse incidence (RI), and 26% (22-30) for treatment-related mortality (TRM) with a range for centres of 36-75%, 10-37%, and 8-54%, respectively. Both methods of analysis showed the centre effect to be highly significant for LFS and TRM, but not for RI. Variables associated with a significantly poor outcome were age over 43 years (p = 0.01), time from diagnosis to first complete remission longer than 65 days (p = 0.02), and centre (p = 0.013) for LFS, and age over 43 years (p = 0.023), time from first complete remission to transplantation of longer than 93 days (p = 0.03), and centre (p = 0.001) for TRM. Moreover, different centres had different prognostic criteria for good-risk or bad-risk patients indicating that risk factors do not have the same impact in each individual centre. Interpretation: The outcome of bone-marrow transplantation for acute myeloid leukaemia in first complete remission is influenced by the centre in which the procedure is done, even with adjustment for known prognostic risk factors. Significant prognostic factors vary among centres, which means that the relative risk is not the same in each individual centre. However, centres may treat populations with different risks of as yet unidentified prognostic factors. Experience may partly account for the difference in outcome among centres.

Original languageEnglish
Pages (from-to)1393-1398
Number of pages6
JournalLancet
Volume355
Issue number9213
Publication statusPublished - Apr 22 2000

Fingerprint

Bone Marrow Transplantation
Acute Myeloid Leukemia
Leukemia
Survival
Mortality
Multivariate Analysis
Recurrence
Incidence
Homologous Transplantation
Proportional Hazards Models
Therapeutics
Transplantation
Pressure
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Frassoni, F., Labopin, M., Powles, R., Mary, J. Y., Arcese, W., Bacigalupo, A., ... Gorin, N. C. (2000). Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet, 355(9213), 1393-1398.

Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. / Frassoni, Francesco; Labopin, Myriam; Powles, Ray; Mary, Jean Yves; Arcese, William; Bacigalupo, Andrea; Bunjes, Donald; Gluckman, Eliane; Ruutu, Tapani; Schaefer, Ulrich W.; Sierra, Jorge; Vernant, Jean Paul; Willemze, Roel; De Witte, Theo; Gorin, Norbert Claude.

In: Lancet, Vol. 355, No. 9213, 22.04.2000, p. 1393-1398.

Research output: Contribution to journalArticle

Frassoni, F, Labopin, M, Powles, R, Mary, JY, Arcese, W, Bacigalupo, A, Bunjes, D, Gluckman, E, Ruutu, T, Schaefer, UW, Sierra, J, Vernant, JP, Willemze, R, De Witte, T & Gorin, NC 2000, 'Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia', Lancet, vol. 355, no. 9213, pp. 1393-1398.
Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet. 2000 Apr 22;355(9213):1393-1398.
Frassoni, Francesco ; Labopin, Myriam ; Powles, Ray ; Mary, Jean Yves ; Arcese, William ; Bacigalupo, Andrea ; Bunjes, Donald ; Gluckman, Eliane ; Ruutu, Tapani ; Schaefer, Ulrich W. ; Sierra, Jorge ; Vernant, Jean Paul ; Willemze, Roel ; De Witte, Theo ; Gorin, Norbert Claude. / Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. In: Lancet. 2000 ; Vol. 355, No. 9213. pp. 1393-1398.
@article{6ed17bf745014606ab9fc0527136acbb,
title = "Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia",
abstract = "Background: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors known previously to influence outcome and a stratified analysis that initially defined, by multivariate analysis, significant variables in this study and then used a proportional-hazard model including centres. Findings: The overall results at 3 years were 57{\%} (95{\%} C1 53-61) for leukaemia-free survival (LFS), 23{\%} (19-27) for relapse incidence (RI), and 26{\%} (22-30) for treatment-related mortality (TRM) with a range for centres of 36-75{\%}, 10-37{\%}, and 8-54{\%}, respectively. Both methods of analysis showed the centre effect to be highly significant for LFS and TRM, but not for RI. Variables associated with a significantly poor outcome were age over 43 years (p = 0.01), time from diagnosis to first complete remission longer than 65 days (p = 0.02), and centre (p = 0.013) for LFS, and age over 43 years (p = 0.023), time from first complete remission to transplantation of longer than 93 days (p = 0.03), and centre (p = 0.001) for TRM. Moreover, different centres had different prognostic criteria for good-risk or bad-risk patients indicating that risk factors do not have the same impact in each individual centre. Interpretation: The outcome of bone-marrow transplantation for acute myeloid leukaemia in first complete remission is influenced by the centre in which the procedure is done, even with adjustment for known prognostic risk factors. Significant prognostic factors vary among centres, which means that the relative risk is not the same in each individual centre. However, centres may treat populations with different risks of as yet unidentified prognostic factors. Experience may partly account for the difference in outcome among centres.",
author = "Francesco Frassoni and Myriam Labopin and Ray Powles and Mary, {Jean Yves} and William Arcese and Andrea Bacigalupo and Donald Bunjes and Eliane Gluckman and Tapani Ruutu and Schaefer, {Ulrich W.} and Jorge Sierra and Vernant, {Jean Paul} and Roel Willemze and {De Witte}, Theo and Gorin, {Norbert Claude}",
year = "2000",
month = "4",
day = "22",
language = "English",
volume = "355",
pages = "1393--1398",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9213",

}

TY - JOUR

T1 - Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia

AU - Frassoni, Francesco

AU - Labopin, Myriam

AU - Powles, Ray

AU - Mary, Jean Yves

AU - Arcese, William

AU - Bacigalupo, Andrea

AU - Bunjes, Donald

AU - Gluckman, Eliane

AU - Ruutu, Tapani

AU - Schaefer, Ulrich W.

AU - Sierra, Jorge

AU - Vernant, Jean Paul

AU - Willemze, Roel

AU - De Witte, Theo

AU - Gorin, Norbert Claude

PY - 2000/4/22

Y1 - 2000/4/22

N2 - Background: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors known previously to influence outcome and a stratified analysis that initially defined, by multivariate analysis, significant variables in this study and then used a proportional-hazard model including centres. Findings: The overall results at 3 years were 57% (95% C1 53-61) for leukaemia-free survival (LFS), 23% (19-27) for relapse incidence (RI), and 26% (22-30) for treatment-related mortality (TRM) with a range for centres of 36-75%, 10-37%, and 8-54%, respectively. Both methods of analysis showed the centre effect to be highly significant for LFS and TRM, but not for RI. Variables associated with a significantly poor outcome were age over 43 years (p = 0.01), time from diagnosis to first complete remission longer than 65 days (p = 0.02), and centre (p = 0.013) for LFS, and age over 43 years (p = 0.023), time from first complete remission to transplantation of longer than 93 days (p = 0.03), and centre (p = 0.001) for TRM. Moreover, different centres had different prognostic criteria for good-risk or bad-risk patients indicating that risk factors do not have the same impact in each individual centre. Interpretation: The outcome of bone-marrow transplantation for acute myeloid leukaemia in first complete remission is influenced by the centre in which the procedure is done, even with adjustment for known prognostic risk factors. Significant prognostic factors vary among centres, which means that the relative risk is not the same in each individual centre. However, centres may treat populations with different risks of as yet unidentified prognostic factors. Experience may partly account for the difference in outcome among centres.

AB - Background: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors known previously to influence outcome and a stratified analysis that initially defined, by multivariate analysis, significant variables in this study and then used a proportional-hazard model including centres. Findings: The overall results at 3 years were 57% (95% C1 53-61) for leukaemia-free survival (LFS), 23% (19-27) for relapse incidence (RI), and 26% (22-30) for treatment-related mortality (TRM) with a range for centres of 36-75%, 10-37%, and 8-54%, respectively. Both methods of analysis showed the centre effect to be highly significant for LFS and TRM, but not for RI. Variables associated with a significantly poor outcome were age over 43 years (p = 0.01), time from diagnosis to first complete remission longer than 65 days (p = 0.02), and centre (p = 0.013) for LFS, and age over 43 years (p = 0.023), time from first complete remission to transplantation of longer than 93 days (p = 0.03), and centre (p = 0.001) for TRM. Moreover, different centres had different prognostic criteria for good-risk or bad-risk patients indicating that risk factors do not have the same impact in each individual centre. Interpretation: The outcome of bone-marrow transplantation for acute myeloid leukaemia in first complete remission is influenced by the centre in which the procedure is done, even with adjustment for known prognostic risk factors. Significant prognostic factors vary among centres, which means that the relative risk is not the same in each individual centre. However, centres may treat populations with different risks of as yet unidentified prognostic factors. Experience may partly account for the difference in outcome among centres.

UR - http://www.scopus.com/inward/record.url?scp=18144443498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144443498&partnerID=8YFLogxK

M3 - Article

C2 - 10791522

AN - SCOPUS:18144443498

VL - 355

SP - 1393

EP - 1398

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9213

ER -